Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically ...
Nature

Complement Activation in Severe COVID-19 Pathophysiology

The complement system, a central arm of innate immunity, comprises a network of plasma and membrane-bound proteins that detect and eliminate pathogens. In severe COVID-19, SARS-CoV-2 triggers ...
MedPage Today on MSN

First complement inhibitor wins full approval in IgA nephropathy

Iptacopan significantly slowed kidney decline in a phase III trial ...
ascopubs.org

Clinicopathologic features of complement activation signatures in colorectal cancer.

Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
BioWorld

C3-targeting siRNA shows promise for Alzheimer’s: findings from cynomolgus monkey study

Previous work uncovered the role of the complement system in neuroinflammation and synaptic loss in neurodegenerative disorders such as Alzheimer’s disease (AD). The third component, C3, central in ...
Healio

‘Important discovery’ shows how complement cascade drives systemic inflammation

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...